Article Per Year (5 Year)
p-Index From 2020 - 2025
0
P-Index
This Author published in this journals
All Journal Jurnal Farmasi Klinik Indonesia
Rahayu, Cherry
Indonesian Journal of Clinical Pharmacy

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Analisis Minimalisasi Biaya Penggunaan Antibiotik Meropenem dan Ceftazidime pada Terapi Febrile Neutropenia Abdulah, Rizky; Kumamba, Raine D.; Sinuraya, Rano K.; Rahayu, Cherry; Barliana, Melisa I.
Indonesian Journal of Clinical Pharmacy Vol 5, No 2 (2016)
Publisher : Indonesian Journal of Clinical Pharmacy

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (567.998 KB) | DOI: 10.15416/ijcp.2016.5.2.132

Abstract

Antibiotik dibutuhkan sebagai salah satu terapi dalam menunjang keberhasilan terapi febrile neutropenia. Beragamnya alternatif terapi antibiotik, menjadikan studi farmakoekonomi diperlukan agar didapatkan terapi yang efektif dan efisien. Tujuan penelitian ini adalah untuk mengetahui antibiotik yang lebih efisien dari segi biaya, yang digunakan dalam terapi febrile neutropenia di salah satu rumah sakit rujukan di kota Bandung selama periode 2011–2013. Penelitian ini merupakan studi observasi analisis, dengan pengambilan data secara retrospektif yang dilakukan pada bulan Februari 2014, melalui data rekam medis pasien rawat inap febrile neutropenia yang mendapatkan terapi antibiotik meropenem atau ceftazidime. Hasil penelitian menunjukkan bahwa walaupun secara statistik tidak menunjukkan perbedaan bermakna, rata-rata total biaya terapi menggunakan antibiotik meropenem adalah sebesar Rp11.094.147, sedangkan rata-rata biaya total perawatan kelompok antibiotik ceftazidime sebesar Rp7.082.523. Hasil penelitian ini diharapkan dapat membantu tenaga profesional kesehatan dalam manajemen terapi febrile neutropenia.Kata kunci: Ceftazidime, farmakoekonomi, febrile neutropenia, meropenemCost Minimization Analysis of the Use of Meropenem and Ceftazidime in Febrile Neutropenia Therapy Use of antibiotics is required in febrile neutropenia therapy. The variety choice on the use of antibiotics has increased the role of pharmacoeconomics study to determine the most effective and efficient antibiotic in a specific area. The purpose of this study was to investigate the lowest cost antibiotic between meropenem and ceftazidime that were used as one of febrile neutropenia treatments at one of referral hospitals in West Java province during 2011–2013. This study was a retrospective, observational and analytical study that was performed on February 2014 by collecting medical record data related to febrile neutropenia inpatient who received meropenem or ceftazidime therapy. The result showed that although it was not statistically significant, the total cost for ceftazidime therapy was IDR7,082,523, which was lower than meropenem therapy (IDR11,094,147). Hopefully, this result can assist the health professionals in the management of febrile neutropenia therapy.Keywords: Ceftazidime, febrile neutropenia, meropenem, pharmacoeconomics
Analisis Minimalisasi Biaya Penggunaan Antibiotik Empirik Pasien Sepsis Sumber Infeksi Pernapasan Purwanti, Okky S.; Abdulah, Rizky; Pradipta, Ivan S.; Rahayu, Cherry
Indonesian Journal of Clinical Pharmacy Vol 3, No 1 (2014)
Publisher : Indonesian Journal of Clinical Pharmacy

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (641.947 KB) | DOI: 10.15416/ijcp.2014.3.1.10

Abstract

Terapi antibiotik empirik merupakan salah satu penunjang keberhasilan dalam pengobatan sepsis. Penelitian ini bertujuan untuk mengetahui kombinasi antibiotik empirik yang paling efisien secara biaya (cost minimization) di antara sefotaksim-eritromisin dan sefotaksim-metronidazol yang digunakan pada sepsis sumber infeksi pernapasan yang dirawat di salah satu rumah sakit di Kota Bandung. Penelitian ini merupakan studi observasional dengan pengumpulan data secara retrospektif tahun 2010–2012. Data diambil dari rekam medis pasien rawat inap sepsis sumber infeksi pernapasan yang mendapat terapi antibiotik empirik sefotaksim-metronidazol atau sefotaksim-eritromisin dan daftar biaya dari bagian akuntansi rumah sakit. Biaya dihitung dari mulai pasien masuk rumah sakit dengan diagnosis sepsis sumber infeksi pernapasan sampai pasien sembuh dari sepsis. Antibiotik efotaksimmetronidazoldan sefotaksim-eritromisin diasumsikan memiliki efek yang sebanding. Pasien dengan terapi empirik sefotaksim-metronidazol memiliki waktu tinggal di rumah sakit lebih lama (25 ibanding11) dan memiliki total biaya rata-rata terapi lebih murah (Rp16.641.112,04 dibandingkan dengan Rp21.641.678,02) daripada pasien dengan terapi empirik sefotaksim-eritromisin. Hasil ini menunjukkan bahwa kombinasi antibiotik sefotaksim-metronidazol lebih efisien secara biaya dibandingkan dengan kombinasi sefotaksim-eritromisin.Kata kunci: Antibiotik empirik, cost minimization, eritromisin, metronidazol, sefotaksim, sepsisCost Minimization Analysis of Empiric Antibiotic Used by Sepsis Patient Respiratory Infection SourceEmpirical antibiotics plays an important role in the therapy of sepsis. The aims of this study was to estimate and compare the cost of treating inpatient sepsis with respiratory infection, with cefotaximemetronidazole or cefotaxime-erythromycin antibiotics. Observational study of cost minimization analysis was conducted by retrospective data from 2010 until 2012. Data were collected from medical records of inpatients sepsis with respiratory infection and received empirical therapy cefotaximemetronidazole or cefotaxime-erythromycin and treatment’s pricelist from department of accounting. Direct medical cost was calculated from empirical antibiotic costs, costs of medical treatment, medical expenses, hospitalization costs, and administrative costs. The study considered the cost from preadmission because sepsis until the patient was fully recovered of sepsis. Cefotaxime-metronidazole and cefotaxime-erythromycin are assumed to have equivalent efficacy. Patients with empirical cefotaxime -metronidazole were found have longer length of stay (25 versus 11) and average total cost of treatmentwas cheaper (16.641.112,04 IDR versus 21.641.678,02 IDR). The findings demonstrate that combination of empirical antibiotic of cefotaxime–metronidazole is more efficient than cefotaxime-erythromycin.Key words: Cost minimizing, cefotaxime, empirical antibiotic erythromycin, metronidazole, sepsis
Analisis Efektivitas Biaya Penggunaan Antibiotik Pasien Sepsis di Rumah Sakit di Bandung Rahayu, Cherry; Purwanti, Okky S.; Sinuraya, Rano K.; Destiani, Dika P.
Indonesian Journal of Clinical Pharmacy Vol 2, No 2 (2013)
Publisher : Indonesian Journal of Clinical Pharmacy

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (597.835 KB)

Abstract

Tujuan penelitian ini adalah untuk mengetahui kelompok kombinasi antibiotik empirik yang paling efektif secara biaya (cost effectiveness) yang digunakan pada sepsis sumber infeksi pernapasan yang dirawat di salah satu rumah sakit di kota Bandung periode tahun 2010–2012. Penelitian merupakan studi analisis observasional dengan pengumpulan data secara retrospektif. Data diambil dari rekam medis pasien rawat inap sepsis sumber infeksi pernapasan dan mendapat terapi antibiotik empirik sefotaksimmetronidazol dan sefotaksim-eritromisin. Komponen biaya yang dikumpulkan meliputi biaya antibiotik empirik, biaya tindakan, biaya penunjang, biaya rawat inap, dan biaya administrasi. Hasil Incremental Cost Effectiveness Ratio (ICER) menunjukkan rasio nilai biaya langsung terhadap pasien yang selamat sebesar Rp 3.301.090,00 untuk kombinasi sefotaksim- metronidazol yang dibandingkan dengan antibiotik empirik lain, sedangkan perbandingan kombinasi sefotaksim-eritromisin dengan antibiotik lain terhadap biaya dan pasien yang selamat sebesar Rp 2.227.366,89. Dapat disimpulkan bahwa kombinasi antibiotik sefotaksim-eritromisin lebih efektif secara biaya dibanding kombinasi sefotaksim-metronidazol.Kata kunci: Antibiotik empirik, cost effectiveness, farmakoekonomi, sepsis Cost Effectiveness Analysis of Antibiotic Used among Sepsis Patients in Hospital in BandungThe aim of this study was to determine the antibiotic combination group that were the most effective in cost (cost effectiveness) used as sepsis with respiratory infections treatment at one of hospital in Bandung. Observational study was conducted by retrospective data. Data were collected from medical record from inpatients sepsis with respiratory infection and received empirical therapy cefotaximemetronidazole or cefotaxime-erythromycin. Direct medical cost is collected from empirical antibiotic costs, costs of medical treatment, medical expenses, hospitalization costs, and administrative costs. The results of Incremental Cost Effectiveness Ratio (ICER) showed that ratio of direct medical cost and survived patients is 3.301.090,00 IDR for cefotaxime-metronidazole that compared to other empirical antibiotic, and 2.227.366,89 IDR for cefotaxime-erythromycin. It can be conclude that the combination of cefotaxime-erythromycin is more cost effective than cefotaxime-metronidazole.Key words: Empirical therapy, cost effectiveness, pharmacoeconomic, sepsis
Co-Authors Barliana, Melisa I. Destiani, Dika P. Kumamba, Raine D. Pradipta, Ivan S. Purwanti, Okky S. Rizky Abdulah Sinuraya, Rano K.